Clinical Spectrum and Outcomes · cSVD Evidence Guide

cSVD is not one clinical syndrome

Small-vessel disease can present as acute ischemic stroke, intracerebral hemorrhage, transient focal neurological episodes, cognitive impairment, gait and balance dysfunction, mood or behavioral change, progressive disability, or an incidental imaging finding. Different vessel pathologies can converge on similar outcomes, and one person can have several manifestations over time R036 R037 R066.

Clinical presentation helps define the population in which a diagnostic criterion or biomarker is being used. It is not merely background description.

1. Acute lacunar ischemic stroke

Classic lacunar syndromes include pure motor stroke, pure sensory stroke, sensorimotor stroke, ataxic hemiparesis, and dysarthria-clumsy hand syndrome. Clinical syndromes are imperfect predictors of a small subcortical infarct, and a small lesion does not prove intrinsic perforator arteriolosclerosis. Parent-artery branch disease, embolism, and other mechanisms remain possible.

The ESO guideline separates acute diagnosis and treatment, progressive lacunar stroke, and secondary prevention, while acknowledging limited evidence for some cSVD-specific questions R063. A research record should preserve symptom onset, syndrome, lesion location, DWI characteristics, parent-vessel assessment, cardiac evaluation, and final mechanism adjudication.

2. Intracerebral hemorrhage

Lobar hemorrhage raises concern for CAA, whereas deep hemorrhage raises concern for deep perforator arteriopathy. Neither location is perfectly specific. Structural lesions, coagulopathy, vascular malformations, tumor, trauma, venous thrombosis, drug exposure, and other causes must be considered.

For suspected CAA, the number and distribution of prior hemorrhagic lesions, cortical superficial siderosis, convexity subarachnoid hemorrhage, nonhemorrhagic MRI markers, and qualifying presentation affect classification and prognosis R006 R009. Clinical decisions after hemorrhage are complicated by competing risks of recurrent ICH, ischemic stroke, and systemic thromboembolism.

3. Transient focal neurological episodes

CAA-associated TFNEs can include spreading sensory symptoms, positive motor phenomena, or negative deficits. They can be related to superficial bleeding and cortical irritation. Differential diagnosis includes TIA, focal seizure, migraine aura, and metabolic or functional episodes. The time course, stereotypy, symptom spread, susceptibility imaging, and acute blood-sensitive imaging are important R004 R009.

The educational lesson is not to label all transient deficits identically. Misclassification can lead to an inappropriate etiologic model and potentially hazardous treatment assumptions.

4. Covert cSVD

WMH and lacunes are often discovered in people without a recognized stroke or cognitive syndrome. Covert is preferable to silent because such findings predict future stroke, cognitive decline, mobility problems, dependency, and death even when no focal event was recognized R062.

Covert disease creates a communication challenge. The imaging finding should be described accurately without declaring a specific vessel pathology. Vascular risks should be assessed in the appropriate clinical setting, but incidental lesions do not justify unvalidated tests or medications. The ESO guideline found limited direct trial evidence and provides context-specific recommendations and consensus statements R062.

5. Vascular cognitive impairment and dementia

VCID spans preclinical, mild, and major levels and often coexists with neurodegenerative disease. Executive dysfunction and slowed processing are common in subcortical vascular injury, but no single cognitive profile is diagnostic. Memory impairment can occur through strategic infarcts, hippocampal injury, disconnection, mixed ADNC, or other mechanisms.

VCING addresses neuropathologic contribution R025, while VasCog-2-WSO provides updated operational diagnostic criteria and biomarker guidance R065. The broader WSO statement integrates epidemiology, neuropathology, cognitive profile, clinical impact, management, mixed dementia, monogenic disease, and trials R066.

Attribution questions

Was cognition measured longitudinally or only once?
Were acute stroke and delirium separated from chronic decline?
Which cognitive domains and functional activities changed?
Were infarcts, hemorrhages, WMH, atrophy, and network injury quantified?
Were AD, LATE-NC, Lewy body, and other pathologies assessed?
Is the analysis estimating total vascular contribution, direct association, or prediction?

6. Gait, balance, falls, and motor slowing

Distributed white-matter and subcortical network injury can impair gait speed, balance, dual-task performance, and motor planning. Associations with WMH and lacunes are common, but arthritis, neuropathy, vestibular disease, medications, vision, frailty, and neurodegeneration are important competing explanations.

Research should use standardized gait measures, record assistive devices and falls, and test whether imaging change precedes functional change. Mobility is a clinically meaningful endpoint and appears in guideline outcome frameworks R062 R063.

7. Mood, apathy, and behavioral manifestations

Depression, apathy, emotional lability, and other behavioral changes can accompany vascular and network injury. These outcomes are influenced by psychosocial context, medications, neurodegeneration, disability, and prior psychiatric disease. Cross-sectional association with WMH does not establish a vascular depression mechanism in an individual.

A useful study separates symptom dimensions, uses longitudinal measurement, and tests spatial or network hypotheses rather than only total WMH volume.

8. Progression and prognosis

cSVD progression can be measured through incident infarcts or hemorrhages, WMH change, new microbleeds, increasing cSS, diffusion change, atrophy, cognitive decline, mobility loss, recurrent stroke, disability, and death. Each endpoint captures a different process.

Composite endpoints increase event counts but can obscure whether an intervention affects clinically meaningful outcomes or only a more frequent imaging marker. A biomarker intended as a trial endpoint needs reliability, longitudinal responsiveness, association with outcome, and evidence that treatment-related change is interpretable.

9. Clinical context changes diagnostic performance

The probability of CAA among older patients after lobar ICH differs from the probability among asymptomatic community participants or memory-clinic patients. Boston v2.0 performance varies accordingly R006 R051 R052. The same principle applies to arteriolosclerosis biomarkers, genetic testing, and quantitative MRI.

Report the intended population with enough detail to reproduce the spectrum:

Referral source and setting.
Qualifying presentation.
Age and key inclusion criteria.
Severity and comorbidity.
MRI availability and exclusions.
Reference-standard availability.
Prior treatment and survival selection.

10. Patient-centered outcomes

The field often privileges lesion volume and cognitive composites because they are measurable. People may care more about independent living, mobility, recurrent stroke, treatment burden, mood, communication, caregiver impact, and uncertainty. A mature knowledge base should connect biomarkers to these outcomes without implying that statistical association equals patient benefit.

11. What is supported

cSVD contributes substantially to ischemic stroke, hemorrhage, cognitive impairment, mobility problems, disability, and death R036 R066.
Covert WMH and lacunes have prognostic significance R062.
Clinical and imaging phenotypes overlap imperfectly.
Mixed vascular and neurodegenerative pathology is common.
Outcome selection determines what a study can claim.

12. What remains uncertain

Which early functional measures best predict meaningful progression.
How to attribute cognitive and gait outcomes in mixed disease.
Which imaging changes are valid treatment-response endpoints.
How syndrome-specific recommendations transport across populations.
How to communicate incidental cSVD without overdiagnosis or undertreatment.

Verification and further study

ESO covert cSVD guideline: R062
ESO lacunar stroke guideline: R063
VasCog-2-WSO criteria: R065
WSO vascular contribution to dementia statement: R066
Post-stroke cognitive impairment guideline: R067
CAA diagnosis and management statement: R009

Sources cited in this chapter

Open the original or authoritative record to verify wording, population, methods, and limitations.